

# **Gentamicin Adult Dosing Treatment**

| Unique Identifier:       | CORP/GUII  | CORP/GUID/313  |               |               |         |
|--------------------------|--|--|---------------|---------------|---------|
| Version Number:          | 5  |  |               |               |         |
| Type of Update / Status: | Ratified with  | n Minor / No T   | echnical Cha  | anges         |         |
| Divisional and           | Pathology,   | Pharmacy   |               |               |         |
| Department:              |  |  |               |               |         |
| Author / Originator and  | Michelle Wo  | ong – Lead Pl  | narmacist, Ar | ntimicrobials |         |
| Job Title:               | Michael Dooney – Lead Pharmacist – CF/Antimicrobials         |  |               |               |         |
|                          | Dr Achyut Guleri – Consultant Microbiologist                 |  |               |               |         |
|                          | Dr Ruth Pal  | Dr Ruth Palmer – Consultant Microbiologist                   |               |               |         |
| Replaces:                | CORP/GUII  | D/313, Versio  | n 4, Gentami  | icin Adult Do | sing    |
|                          | Treatment  |  |               |               |         |
| Description of           |  | Include in the policy that a gentamicin calculator should be |               |               |         |
| amendments:              | used to calculate initial gentamicin dose and amended action |  |               |               |         |
|                          | if pre-dose between 1-2mg/L                                  |  |               |               |         |
| Approved by:             | Medicine Management and Safety Review Committee              |  |               |               |         |
| Approved Date:           | 18/02/2021   |  |               |               |         |
| Issue Date:              | 18/02/2021   |  |               |               |         |
| Review Date from Date    | 1 Year   | 2 Years  | 3 Years       | 4 Years       | 5 Years |
| of Approval:             |  | $\boxtimes$  |               |               |         |
|                          |  | 18/02/2023   |               |               |         |

#### 

| dd/mm/yy | version | Author  | Reason for changes   |
|----------|---------|---|--|
| 21/12/17 | 4       | Michelle Wong – Lead Pharmacist, Antimicrobials Michael Dooney – Lead Pharmacist – CF/Antimicrobials Dr Achyut Guleri – Consultant Microbiologist Dr Ruth Palmer – Consultant Microbiologist Dr Rashmi Sharma - Consultant Microbiologist | Clarified age parameter that requires 3mg/kg dose – should be greater or equal to 70years. Removed max dose of 80mg for multiple daily dose in line with BSAC guidelines. Advice to monitor for side effects |
| 18/02/21 | 5       | Michelle Wong – Lead Pharmacist, Antimicrobials Michael Dooney – Lead Pharmacist – CF/Antimicrobials Dr Achyut Guleri – Consultant Microbiologist Dr Ruth Palmer – Consultant Microbiologist  | Include in the policy that<br>a gentamicin calculator<br>should be used to<br>calculate initial<br>gentamicin dose and<br>amended action if pre-<br>dose between 1-2mg/L                                     |

| Consultation / Acknowledgements with Stakeholders |                                     |                           |
|---|-------------------------------------|---------------------------|
| Name  | Designation                         | Date Response<br>Received |
| Dr Guleri/Dr Palmer                               | Consultant microbiologists          | 02/2/2021                 |
| Noel Topping                                      | Lead pharmacist - cardiology        |                           |
| Hannah Sheridan                                   | Lead pharmacist – A+E               |                           |
|   | Microbiology Quality and Governance | 04/02/2021                |
| Meeting   |                                     |                           |

| Revision No: 5  Next Review Date: 18/02/2023 |                                | VIANTEN BRINTER |  |  |  |
|--|--------------------------------|-----------------|--|--|--|
|  | UNCONTROLLED COPY WHEN PRINTED |                 |  |  |  |

### **CONTENTS**

| Versior                | Control Sheet  | 1  |
|------------------------|--|----|
| Consul                 | ation / Acknowledgements with Stakeholders                                   | 2  |
|                        | roduction / Purpose  |    |
|                        | neral Principles / Target Audience   |    |
|                        | finitions and Abbreviations  |    |
|                        | sponsibilities (Ownership and Accountability)                                |    |
|                        | ideline  |    |
| 5 G<br>5.1             | Extended Interval Gentamicin Dosing  |    |
| 5.1<br>5.1             |  | 3  |
| J. I                   | treatment dose – requires log in to NEXUS – under pre-installed app          | 6  |
| 5.1                    |  |    |
| 0.1                    | and Indicate on the Drug Chart the Need to Monitor Pre-dose Level before     | ١  |
|                        | 2nd Dose   | 6  |
| 5.1                    |  |    |
|                        | Due)   | 6  |
| 5.1                    | ,  |    |
| 5.1                    | ,  |    |
| 5.1                    | 6 Monitoring Continuing Therapy  | 7  |
| 5.2                    | Elderly / Renal (CrCl 10-29.9ml/min) Gentamicin Dosing                       | 8  |
| 5.2                    | 3, 3, 1, 3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,                           |    |
|                        | treatment dose - requires log in to NEXUS - under pre-installed app          |    |
| 5.2                    | ,  |    |
|                        | Chart  |    |
| 5.2                    | J  |    |
| 5.2                    | 1 3  |    |
|                        | Traditional Multiple Daily Dosing of Gentamicin                              |    |
| 5.3                    |  |    |
| 5.3                    |  |    |
| 5.3<br>5.3             |  |    |
| 5.3                    | 1 0  |    |
|                        | How to calculate IBW and Adjusted Body Weight1                               |    |
| 5. <del>4</del><br>5.5 | How to calculate reatinine clearance   |    |
| 5.6                    | Documentation1   |    |
| 5.6                    |  |    |
| 5.6                    | <u> </u>   |    |
|                        | ferences and Associated Documents1   |    |
|                        | x 1: Extended interval gentamicin dosing guidelines summary (Adults)1        |    |
|                        | x 2: Elderly/Renal (CrCl 10-29.9ml/min) gentamicin dosing guidelines summary | _  |
|                        | dults)   | _  |
| `                      | ,  |    |
|                        | x 3: Traditional multiple daily dosing guidelines summary (Adults)1          |    |
|                        | x 4: Maximum Body Weight/ Ideal Body Weight Table1                           |    |
|                        | x 5: Gentamicin Flow Chart1  |    |
| Append                 | x 3: Equality Impact Assessment Form Error! Bookmark not defined             | ı. |

| Blackpool Teaching             | Hospitals NHS Foundation Trust       | ID No. CORP/GUID/313                     |  |  |
|--------------------------------|--------------------------------------|--|--|--|
| Revision No: 5                 | Next Review Date: 18/02/2023         | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED |                                      |  |  |  |
|                                | Current Version held on the Intranet |  |  |  |

#### 1 Introduction / Purpose

To ensure adequate dosing of gentamicin to effectively treat infection in adult patients, whilst protecting patients from toxicity due to overdose.

Gentamicin is an effective and valuable antibiotic for the treatment of infections due to Gram negative organisms. Gentamicin is administered intravenously and dosing must be adjusted for the patient's renal function and serum levels monitored to reduce the risk of the serious adverse effects of nephrotoxicity and ototoxicity. Prescribers should inform patients of these important side effects.

There is some evidence to suggest an association between mitochondrial mutations (particularly the m.1555A>G mutation) with an increased risk of this ototoxicity. Consider the need for genetic testing especially in patients requiring recurrent or long-term treatment with aminoglycosides, but do not delay urgent treatment in order to test. To minimise the risks of adverse events, including ototoxicity, continuous monitoring (before, during and after treatment) of renal function (serum creatinine, creatinine clearance) and auditory function (consider formal audiology review if longer duration), as well as hepatic and laboratory parameters, is recommended for all patients

Gentamicin can be dosed using one of two dosing regimens:

- Extended interval (once daily) dosing
- Traditional multiple daily dosing.

Extended interval dosing (also known as "once-daily gentamicin") involves the use of a 5mg/kg dose administered as a 30-60minute infusion. The dosage interval (24, 36 or 48-hourly) is adjusted to ensure that serum levels fall below 1mg/L for at least 4 hours of the dosing interval. Selecting the optimum-dosing interval is achieved by monitoring pre-dose levels. Blood sampling is repeated after dose interval changes and twice weekly thereafter if renal function and fluid balance are stable. Extended interval gentamicin dosing has been found to be at least as effective as traditional multiple daily dosing and no more nephrotoxic. This dosing regime is also less complex to administer and monitor, therefore making it the dosing regimen of choice.

Traditional multiple daily dosing is used for the treatment of endocarditis.

This guideline provides advice on the dosing and monitoring of gentamicin using all regimens and taking into account the patient's renal function/age to ensure the most effective and safest dosing of this antibiotic.

#### 2 General Principles / Target Audience

This guideline is relevant to all staff involved in the prescribing, monitoring, administrating gentamicin using any of 3 dosing regimes.

 Dosing of gentamicin using the <u>high-dose extended interval regimen</u>, for the treatment of Gram negative sepsis.

| Blackpool Teaching I   | Hospitals NHS Foundation Trust | ID No. CORP/GUID/313 Title: Gentamicin Adult Dosing Treatment |  |  |
|--|--------------------------------|---|--|--|
| Revision No: 5   | Next Review Date: 18/02/2023   | Title. Gentamicin Addit Dosing Treatment                      |  |  |
| UNCONTROLLED COPY WHEN PRINTED  Current Version held on the Intranet |                                |   |  |  |

- Dosing of gentamicin in <u>elderly patients or those with severe renal impairment</u> (CrCl 10-29.9ml/min) for the treatment of Gram negative sepsis.
- Dosing of gentamicin by <u>traditional multiple daily dosing</u> for infective endocarditis in adults.

#### 3 Definitions and Abbreviations

CrCl Creatinine Clearance IBW Ideal Body Weight

#### 4 Responsibilities (Ownership and Accountability)

Prescribers should follow this guide when prescribing and monitoring gentamicin.

Nursing staff should follow this guide when administrating and monitoring gentamicin.

Pharmacists should follow this guide when advising on the prescribing and monitoring of gentamicin.

#### 5 Guideline

#### 5.1 Extended Interval Gentamicin Dosing

Click here for quick reference guideline.

This dosing regime is for the treatment of Gram negative sepsis in patients WITHOUT severe renal impairment (CrCl ≥30mL/min) - see section 6.5 on how to calculate creatinine clearance (CrCl).

**Do NOT** use this extended interval dosing for the following groups of patients (without discussion with pharmacist or microbiologist).

- Bronchiectasis
- Burns (>20% body surface area)
- Cystic fibrosis
- Ascites
- Infective endocarditis
- Renal impairment (Creatinine clearance <30mL/min), unstable or deteriorating renal function
- Renal dialysis.

| Blackpool Teaching He   | ospitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |
|---|-------------------------------|--|--|
| Revision No: 5  | Next Review Date: 18/02/2023  | Title: Gentamicin Adult Dosing Treatment |  |
| UNCONTROLLED COPY WHEN PRINTED Current Version held on the Intranet |                               |  |  |

# 5.1.1 Calculate Dose (5mg/kg) – use gentamicin calculator to calculate initial treatment dose – requires log in to NEXUS – under pre-installed app

Standard dose is 5mg/kg (max. 500mg) for gentamicin based upon actual body weight or adjusted body weight, rounded to the nearest 20mg.

If the patient is not obese, use the actual body weight to calculate the starting dose.

If the patient is obese (20% over ideal body weight), use the adjusted body weight to calculate the starting dose (see appendix 4 to determine the need to use adjusted body weight and how to calculate adjusted body weight).

# 5.1.2 Prescribe the First Dose on the Regular Antibiotics Section on the Drug Chart and Indicate on the Drug Chart the Need to Monitor Pre-dose Level before 2nd Dose

Check Gentamicin has not been given in the last 24 hours before prescribing or administering Gentamicin – check all current and previous prescriptions / A+E paperwork if applicable.

- Clear documentation and handover of critical medicines is essential to prevent errors.
- Communication of stat doses between prescriber and ward essential.

Dose to be administered, diluted in 100mL sodium chloride 0.9% or glucose 5%, over 30 - 60 minutes.<sup>1,9</sup>

### 5.1.3 Monitor Pre-Dose Level before 2nd Dose (1-4 Hours Before Next Dose Is Due)

Gentamicin is a nephrotoxic drug. Monitoring of pre-dose levels is required to ensure that the drug has been sufficiently cleared (pre-dose <1mg/L) from the body. Post-dose monitoring of levels is NOT required.

Where gentamicin is being used as a single dose either in surgical prophylaxis or adjuvant treatment, there is no need to take pre-dose levels as no subsequent doses are intended.

#### 5.1.4 Interpreting Gentamicin Level

#### If NORMAL AND STABLE RENAL FUNCTION:

Monitor pre-dose level before 2nd dose, GIVE 2nd dose without waiting for level and review the result of the pre-dose level before prescribing and administering 3rd or subsequent doses.

Target pre-dose level LESS THAN 1mg/L

| Blackpool Teaching Ho  | ospitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |  |
|--|-------------------------------|--|--|--|
| Revision No: 5   | Next Review Date: 18/02/2023  | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED  Current Version held on the Intranet |                               |  |  |  |

#### Normal pre-dose level (<1mg/L)

- Continue current regimen
- Repeat pre-dose levels after 3-4 days if renal function remains stable

#### Pre-dose level 1-2mg/L (and renal function unchanged)

- Check level taken at the correct time (1-4 hours before next dose was due)
- Increase the dosing interval to 36 or 48-hourly (must monitor clinical response and if not responding – review treatment choice)

#### Pre-dose level greater than 2mg/L

- Check level taken at the correct time (1-4 hours before next dose was due)
- Omit any further doses of gentamicin and discuss with Microbiology
- The need for gentamicin therapy MUST be reviewed

If the pre-dose level was not taken at the correct time the reported result must be interpreted with caution. Speak to pharmacy or microbiology for advice in this situation.

If the patient cannot safely be maintained on an extended interval dosing regimen, consider the renal dosing regimen.

#### **5.1.5 Prescribing Subsequent Doses**

Subsequent doses may be prescribed on the regular section of the drug chart, and administration boxes MUST be marked to ensure the correct dosing interval is followed, and indicate when the next level is due.

#### **5.1.6 Monitoring Continuing Therapy**

Repeat pre-dose level monitoring and serum creatinine twice weekly or more frequently in patients with unstable renal function.

Repeat pre-dose level monitoring **daily** if adjustments are being made or if the patient is **renally impaired**.

Assess the need for gentamicin daily and monitor for renal / ototoxicity.

#### **Please Note**

Gentamicin therapy is rarely required beyond 48 - 72 hours, with the exception of endocarditis. Any course intended beyond 48 - 72 hours MUST be discussed with a Consultant Microbiologist. The risk of nephrotoxicity and ototoxicity increases with prolonged course length.

| Blackpool Teaching Hos               | spitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |
|--------------------------------------|------------------------------|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023 | Title: Gentamicin Adult Dosing Treatment |  |
| UNCONTROLLED COPY WHEN PRINTED       |                              |  |  |
| Current Version held on the Intranet |                              |  |  |

#### 5.2 Elderly / Renal (CrCl 10-29.9ml/min) Gentamicin Dosing

Click here for quick reference guideline.

This dosing regime should be used where the prescriber wishes to use an extended interval gentamicin dosing regime for the treatment of Gram negative sepsis in patients WITH severe renal impairment (Creatinine clearance <30mL/min- but discuss with microbiologist or pharmacy if <10mL/min or anuric) or elderly patients e.g. greater or equal to 70years.

# 5.2.1 Calculate Renal Dose (3mg/kg) - use gentamicin calculator to calculate initial treatment dose – requires log in to NEXUS – under pre-installed app

If the patient is not obese, use the actual body weight to calculate starting dose, (round to nearest 20mg).

If the patient is obese (20% over IBW), use the adjusted body weight to calculate starting dose. (See appendix 4 to determine the need to use adjusted body weight and how to calculate adjusted body weight).

## 5.2.2 Prescribe the First Dose on the "Once Only" Section on the Front of the Drug Chart

Check Gentamicin has not been given in the last 24 hours before prescribing or administering Gentamicin— check all current and previous prescriptions / A+E paperwork if applicable.

- Clear documentation and handover of critical medicines is essential to prevent errors.
- Communication of stat doses between prescriber and ward essential.

No subsequent doses should be prescribed on the regular section of the drug chart until a pre- dose level is taken and reviewed.

Dose to be administered, diluted in 100mL sodium chloride 0.9% or glucose 5%, over 30-60 minutes. 1.9

#### 5.2.3 Take Level Immediately Before 2nd Dose Is Due

**WAIT** for level result.

#### 5.2.4 Interpreting Gentamicin Level Result

Target pre-dose level LESS THAN 1mg/L

| Blackpool Teaching Hos               | spitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |
|--------------------------------------|------------------------------|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023 | Title: Gentamicin Adult Dosing Treatment |  |
| UNCONTROLLED COPY WHEN PRINTED       |                              |  |  |
| Current Version held on the Intranet |                              |  |  |

#### If level less than 1mg/L

- Prescribe 2nd dose on "once only" section of drug chart or regular section (highlighting the need to wait for pre-dose level)
- Repeat level 24 hours after dose administered (pre-dose before the next dose due)

#### If level 1mg/L OR greater than 1mg/L

- Do NOT prescribe any further doses
- Check level taken at the correct time (1-4 hours before next dose was due)
- Repeat level 24 hours later if it was taken at the correct time
- If level < 1mg/L, prescribe 2nd dose on "once only" section of drug chart or regular section (highlighting the need to wait for pre-dose level)
- If level still remains >1mg/L, keep repeating gentamicin level at periodic intervals until gentamicin level has fallen to <1mg/L

No further doses should be prescribed or administered until level is <1 mg/L

If the pre-dose level was not taken at the correct time the reported result must be interpreted with caution. Speak to pharmacy or microbiology for advice in this situation

DAILY levels are required for patients on the renal/elderly gentamicin dosing regimen or those with unstable renal function.

Assess the need for gentamicin daily and monitor for renal/ototoxicity.

Please Note: Gentamicin therapy is rarely required beyond 48 – 72 hours, with the exception of endocarditis. Any course intended beyond 48 hours in patients with CrCl <30mL/min MUST be discussed with a Consultant Microbiologist. The risk of nephrotoxicity and ototoxicity increases with prolonged courses.

#### 5.3 Traditional Multiple Daily Dosing of Gentamicin

Click here for quick reference quideline.

This dosing regime is for the treatment of patients with **endocarditis**.

#### 5.3.1 Calculate Dose

1mg/kg 12hourly (modify according to renal function and levels) round to the nearest 20mg.

If patient is not obese, use actual body weight to calculate starting dose.

| Blackpool Teaching Hos               | spitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |
|--------------------------------------|------------------------------|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023 | Title: Gentamicin Adult Dosing Treatment |  |
| UNCONTROLLED COPY WHEN PRINTED       |                              |  |  |
| Current Version held on the Intranet |                              |  |  |

If patient is obese (20% over IBW), use adjusted body weight to calculate starting dose. (See appendix 4 to determine the need to use adjusted body weight and how to calculate adjusted body weight).

#### 5.3.2 Prescribe Gentamicin at Chosen Dose and Dose Interval

The dosing regimens recommended above are starting dose regimens only. Blood levels must be monitored to ensure target peaks and troughs are achieved.

Dose to be administered as intravenous bolus over 3-5 minutes. 1,9

#### 5.3.3 Monitoring Drug Levels

Check **pre-dose** (trough) level around the 3rd or 4th dose before administering the dose.

Administer dose. There is no need to wait for pre-dose level before administering dose, unless instructed to do so by your ward pharmacist or Consultant Microbiologist.

Check one hour post-dose (peak) level around the 3rd or 4th dose. Level to be taken one hour after completion of the bolus / infusion.

If renally impaired, check around the 2<sup>nd</sup> dose.

Label your sample tubes and request form clearly with pre and post dose level as appropriate.

### 5.3.4 Interpreting Gentamicin Levels

BNF target blood levels are as follows:

|  | Gentamicin        |                           |  |
|--|-------------------|---------------------------|--|
| Indication                             | Pre-dose (trough) | One hour post dose (peak) |  |
| Infective endocarditis – gram positive | Less than 1mg/L   | 3-5mg/L                   |  |

#### 5.3.4.1 Pre-dose levels:

#### Normal pre-dose (<1mg/L)

- Regimen can be continued
- Further pre-dose levels MUST be monitored twice weekly so long as renal function is stable

| Blackpool Teaching                          | Hospitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |  |
|---|--------------------------------|--|--|--|
| Revision No: 5 Next Review Date: 18/02/2023 |                                | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED              |                                |  |  |  |
| Current Version held on the Intranet        |                                |  |  |  |

#### Pre-dose level is between 1-3mg/L (and renal function unchanged)

- Check level taken at the correct time (1-4 hours before next dose was due)
- Increase the dosing interval e.g. from 12-hourly to 24-hourly

#### Pre-dose greater than 3mg/L

- Check level taken at the correct time (1-4 hours before next dose was due)
- Further gentamicin doses MUST be withheld
- Discuss with microbiology before recommencing therapy

#### 5.3.4.2 One-hour post-dose levels:

#### Post-dose level is below the target range (<3mg/L)

- Check level taken at the correct time (1 hour after the completion of infusion/bolus)
- Gentamicin is subtherapeutic
- The dose should be increased

# Post-dose level is above the target range (>5mg/L); pre-dose level is normal (<1mg/L)

- Check levels taken at the correct time
- Reduce the dose

# Both the post-dose (>5mg/L) and pre-dose (>1mg/L) levels are above the target range

- Check levels taken at the correct time
- The next dose(s) MUST be omitted
- Discuss with Microbiology before recommencing therapy

If the pre- and/or post-dose level were not taken at the correct time the reported result must be interpreted with caution. Speak to pharmacy or microbiology for advice in this situation

Please contact your ward Pharmacist or Consultant Microbiologist for advice on changes to the dose and / or dosing interval.

| Revision No: 5                 | Next Review Date: 18/02/2023 | VIANTEN BRINTER |  |  |
|--------------------------------|------------------------------|-----------------|--|--|
| UNCONTROLLED COPY WHEN PRINTED |                              |                 |  |  |

#### 5.3.5 Monitoring Continuing Therapy

Repeat drug level monitoring (peak and trough) levels and serum creatinine twice weekly, or more frequently if renally impaired.

Monitor for renal/ototoxicity.

#### 5.4 How to calculate IBW and Adjusted Body Weight

Calculate the IBW first (or see appendix 4 - IBW table), then use IBW to calculate the adjusted body weight.

IBW men  $(kg) = 50 + 2.3 \times every$  inch over 5 feet IBW women  $(kg) = 45.5 + 2.3 \times every$  inch over 5 feet

Adjusted body weight (Adj BW) = IBW + 0.4x (actual body weight – IBW)

#### 5.5 How to calculate creatinine clearance

Click here for Creatinine Clearance calculator to estimate renal function

If the above hyperlink fails, please use the formula below to calculate Creatinine Clearance:

CrCl (mL/min) = F x (140-age) x weight\* (kg)

Serum creatinine (micromoles/L)

Where F=1.23 for males and 1.04 for females

\*If obese (>20% above IBW): Use Adjusted Body Weight (Adj BW) - see 3.4

#### 5.6 Documentation

#### 5.6.1 Monitoring

The time of gentamicin dosing MUST be clearly prescribed on the prescription. However, nursing staff must document the <u>EXACT</u> time of administration and <u>EXACT</u> time of sampling in the medical notes and cyberlab to facilitate interpretation of the results.

Example to be documented in the patient's medical notes:

Gentamicin is prescribed at 10:00 regularly (24hour clock)

**Exact** time of gentamicin given:......10:00.....

| Blackpool Teaching Hospitals NHS Foundation Trust |  | ID No. CORP/GUID/313                     |  |  |
|---|--|--|--|--|
| Revision No: 5 Next Review Date: 18/02/2023       |  | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED                    |  |  |  |  |
| Current Version held on the Intranet              |  |  |  |  |

#### 5.6.2 Critical timing

If delay in the administration of gentamicin (greater than 1 hour) - the time of late administration must be documented on prescription chart and reason must be documented in the medical notes. This is particularly important for time critical antibiotic like gentamicin as the next dose may need to be delayed if previous dose given late.

#### 6 References and Associated Documents

- 1. **Medicines Complete.** Gentamicin. [Online] Last Update: 22-Jan-2021. [Cited: 02 03 2021.] https://www.medicinescomplete.com/#/content/bnf/\_632013114?hspl=gentamicin. https://doi.org/10.18578/BNF.632013114.
- 2. **NICE BNF.** Gentamicin. [Online] [Cited: 02 03 2021.] https://bnf.nice.org.uk/drug/gentamicin.html.
- 3. **Nicolau DP, et al.** Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrob Agents Chemother. 1995 Mar; 39(3): 650–655.* [Online] 03 1995. [Cited: 02 03 2021.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC162599/. doi: 10.1128/AAC.39.3.650. PMCID: PMC162599. PMID: 7793867.
- 4. **Barza M, et al.** Single or multiple daily doses of aminoglycosides: a meta-analysis. *BMJ.* 1996 Feb 10; 312(7027): 338–345. [Online] 10 02 1996. [Cited: 02 03 2021.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350289/. doi: 10.1136/bmj.312.7027.338. PMCID: PMC2350289. PMID: 8611830.
- 5. **R Ferriols-Lisart, M Alós-Almiñana.** Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. *American Journal of Health-System Pharmacy, Volume 53, Issue 10, 15 May 1996, Pages 1141–1150.* [Online] 05 1996. [Cited: 02 03 2021.] https://academic.oup.com/ajhp/article-abstract/53/10/1141/5094118. doi: 10.1093/ajhp/53.10.1141.
- 6. **Bailey TC, et al.** A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis. 1997 May;24(5):786-95.* [Online] 05 1997. [Cited: 02 03 2021.] https://pubmed.ncbi.nlm.nih.gov/9142771/. doi: 10.1093/clinids/24.5.786. PMID: 9142771.
- 7. **emc.** Genticin (Gentamicin) 40mg/ml Injectable. [Online] Last updated on emc: 24 Apr 2018. [Cited: 02 03 2021.] https://www.medicines.org.uk/emc/product/6553/smpc.
- 8. Royal College of Obstetricians & Gynaecologists. Sepsis in Pregnancy, Bacterial (Green-top Guideline No. 64a). [Online] Published: 25/04/2012. [Cited: 02 03 2021.] https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg64a/.
- 9. **Gould FK, et al.** Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. *Antimicrob Chemother.* 2012 Feb;67(2):269-89. Epub 2011 Nov 14. [Online] 02 2012. [Cited: 02 03 2021.] https://pubmed.ncbi.nlm.nih.gov/22086858/. doi: 10.1093/jac/dkr450.
- 10. **Medicines and Healthcare products Regulatory Agency.** Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. [Online] Published: 07/01/2021. [Cited: 02 03 2021.] https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations.
- 11. NHS UKMi. How should antibiotics be dosed in obesity? 2013.

| Blackpool Teaching                   | Hospitals NHS Foundation Trust | ID No. CORP/GUID/313 Title: Gentamicin Adult Dosing Treatment |  |  |
|--------------------------------------|--------------------------------|---|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023   | This contains that I come in the contains the                 |  |  |
| UNCONTROLLED COPY WHEN PRINTED       |                                |   |  |  |
| Current Version held on the Intranet |                                |   |  |  |

| Appendix 1: Extended interval gentamicin dosing guidelines summary (Adults)      |   |  |  |
|--|---|--|--|
| Click here for full guideline  |   |  |  |
| Introduction   | Preferred regimen for the treatment of Gram negative sepsis  Do NOT use extended interval dosing for the following groups of patients: (without discussion with pharmacist or microbiologist)  • Bronchiectasis  • Burns (>20% body surface area)  • Cystic fibrosis  • Ascites  • Infective endocarditis  • Renal impairment (Creatinine clearance <30mL/min), unstable or deteriorating renal function (see Renal dosing)  • Renal dialysis |  |  |
| Dose regimen   | Gentamicin dose = 5mg/kg (maximum 500mg) Use adjusted body weight if obese (i.e. if 20% over ideal body weight) Round to nearest 20mg e.g.260mg if 50kg, 300mg if 60kg, 360mg if 70kg, 400mg if 80kg  |  |  |
| Prescribing first dose   | Check no previous dose given in last 24hours. May prescribe on regular antibiotics section and indicate on the drug chart the need to monitor Pre-dose Level before 2 <sup>nd</sup> Dose  |  |  |
| Administration   | Dilute with 100mL sodium chloride 0.9% or glucose 5% and give by IV infusion over 30-60mins   |  |  |
| What levels should I monitor?  | <b>Pre-dose level</b> before 2 <sup>nd</sup> dose (1-4 hours before next dose is due)   |  |  |
| When should I take levels initially?   | Check before 2 <sup>nd</sup> dose due (unless single dose therapy)  |  |  |
| Target assay levels  | Pre-dose level LESS THAN 1mg/L  |  |  |
| Recommendations  | Normal pre-dose level (<1mg/L)  |  |  |
| for dose adjustment  | -Continue current regimen   |  |  |
| based on levels -Repeat pre-dose levels after 3-4 days if renal function remains |   |  |  |
| being taken at   |   |  |  |
| correct time   | Pre-dose level 1-2mg/L (and renal function unchanged) -Increase the dosing interval to 36 or 48-hourly (review if not responding)   |  |  |
|  | Pre-dose level greater than 2mg/L -Omit any further doses of gentamicin and discuss with Microbiology -The need for gentamicin therapy MUST be reviewed  If the patient cannot safely be maintained on an extended interval dosing  |  |  |
|  | regimen, consider the renal dosing regimen.   |  |  |
| Do I need to wait for  | IF NORMAL and STABLE RENAL FUNCTION - Monitor pre-dose  |  |  |
| the level result?  | level before 2 <sup>nd</sup> dose, GIVE 2 <sup>nd</sup> dose without waiting for level and review for the result of the pre-dose level before prescribing and administering 3 <sup>rd</sup> or subsequent doses   |  |  |
| When should I repeat levels?   | Check pre-dose levels every 3-4 days if renal function remains stable.  Monitor pre-dose levels <b>daily</b> if adjustments are being made or if the patient is <b>renally impaired</b> .  Review need daily and monitor for renal/ototoxicity  |  |  |
| How do I prescribe subsequent doses?   | Subsequent doses may be prescribed on the regular section of the drug chart, and administration boxes MUST be marked to ensure the correct dosing interval is followed, and indicate when the next level is due.  |  |  |

| Blackpool Teaching Hospitals NHS Foundation Trust |  | ID No. CORP/GUID/313                     |  |  |
|---|--|--|--|--|
| Revision No: 5 Next Review Date: 18/02/2023       |  | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED                    |  |  |  |  |
| Current Version held on the Intranet              |  |  |  |  |

| Appendix 2: Elderly/Renal (CrCl 10-29.9ml/min) gentamicin dosing guidelines summary (Adults) |   |  |  |
|--|---|--|--|
| Click here for full guideline  |   |  |  |
| Introduction   | This regimen should be used where the prescriber wishes to use an extended interval gentamicin dosing regimen for the treatment of Gram negative sepsis in patients WITH severe renal impairment (CrCl <30ml/min, but if <10ml/min or anuric - discuss with microbiologist or pharmacy) or elderly patients e.g. greater or equal to 70years  |  |  |
| Dose regimen   | Gentamicin dose = 3mg/kg (maximum 300mg) Use adjusted body weight if obese (i.e. if 20% over ideal body weight) Round to nearest 20mg e.g.160mg if 50kg, 180mg if 60kg, 220mg if 70kg, 240mg if 80kg  |  |  |
| Prescribing first dose   | Check no previous dose given in last 24hours Prescribe the first dose on the "once only" section of the drug chart  |  |  |
| Administration   | Dilute with 100mL sodium chloride 0.9% or glucose 5% and give by IV infusion over 30-60minutes  |  |  |
| What levels should I   | <b>Pre-dose level</b> before 2 <sup>nd</sup> dose (1-4 hours before next dose is due)   |  |  |
| monitor?   |   |  |  |
| When should I take levels initially?   | Check before 2 <sup>nd</sup> dose due (unless single dose therapy)  |  |  |
| Target assay levels  | Pre-dose level LESS THAN 1mg/L  |  |  |
| Recommendations  | If level less than 1mg/L  |  |  |
| for dose adjustment<br>based on levels<br>being taken at<br>correct time                     | <ul> <li>Prescribe 2<sup>nd</sup> dose on "once only" section of drug chart or regular section of the chart (but highlighting the need to wait for pre dose level before administration.</li> <li>Repeat level 24 hours after dose administered (pre-dose before the next dose due)</li> <li>If level 1mg/L OR greater than 1mg/L         <ul> <li>Do NOT prescribe any further doses</li> <li>Repeat level 24 hours later</li> <li>If level &lt; 1mg/L, prescribe 2<sup>nd</sup> dose on "once only" section of drug chart or regular section of the chart (but highlighting the need to wait for pre dose level before administration.</li> <li>If level still remains &gt;1mg/L, keep repeating gentamicin level at periodic intervals until gentamicin level has fallen to &lt;1mg/L</li> </ul> </li> <li>No further doses should be prescribed or administered until level is &lt;1mg/L</li> </ul> |  |  |
| Do I need to wait for the level result?  | WAIT for the result of the pre-dose level before prescribing and administering any subsequent doses   |  |  |
| When should I repeat levels?   | DAILY levels are required for patients on the renal gentamicin dosing regimen or those with unstable renal function.  |  |  |
| How do I prescribe subsequent doses?   | Subsequent doses may be prescribed on the "once only" section of the drug chart or regular section of the chart (but highlighting the need to wait for pre dose level before administration. Doses should only be administered once the pre-dose level is less than 1mg/L.  |  |  |
| Continuation of treatment  | If the patient requires gentamicin beyond 48 hours, this MUST be discussed with a Consultant Microbiologist. The risk of nephrotoxicity and ototoxicity increases with prolonged courses.   |  |  |

| ID No. CORP/GUID/313                     |  |  |  |  |
|--|--|--|--|--|
| Title: Gentamicin Adult Dosing Treatment |  |  |  |  |
| UNCONTROLLED COPY WHEN PRINTED           |  |  |  |  |
| Current Version held on the Intranet     |  |  |  |  |
|  |  |  |  |  |

| Annendiy 3: Tradit   | ional multiple daily dosing guidelines summary (Adults)  |  |  |  |  |
|--|--|--|--|--|--|
|  | Click here for full guideline  |  |  |  |  |
| Introduction   | Treatment of patients with endocarditis.   |  |  |  |  |
| Dose regimen   | 1mg/kg 12 hourly - modified according to renal function and level (round to  |  |  |  |  |
| Creatinine   | nearest 20mg). Use adjusted body weight if obese (i.e. if 20% over ideal   |  |  |  |  |
| Clearance calculator   | body weight)   |  |  |  |  |
| Prescribing first  | Prescribe gentamicin at chosen dose and dose interval  |  |  |  |  |
| dose   | Troothbo gontarmon at onoden dode and dode interval  |  |  |  |  |
|  | The dosing regimens recommended above are starting dose regimens only. Blood levels must be monitored to ensure target peaks and troughs are achieved. |  |  |  |  |
| Administration   | IV bolus over 3-5 minutes. Dilution is not normally necessary.   |  |  |  |  |
| What levels should   | Check Pre and Post dose levels around the 3 <sup>rd</sup> or 4 <sup>th</sup> dose.   |  |  |  |  |
| I monitor?   | If renally impaired, check around the 2 <sup>nd</sup> dose.  |  |  |  |  |
| When should I take   | Check pre-dose (trough) level around the 3 <sup>rd</sup> or 4 <sup>th</sup> dose before  |  |  |  |  |
| levels initially?  | administering the dose.  |  |  |  |  |
|  | Administer dose. There is no need to wait for pre-dose level to be reported  |  |  |  |  |
|  | before administering dose, unless instructed to do so by your ward pharmacist or Consultant Microbiologist.  |  |  |  |  |
|  | Chook and hour past does (neels) level around the 3rd on 4th does does   |  |  |  |  |
|  | Check one hour post-dose (peak) level around the 3 <sup>rd</sup> or 4 <sup>th</sup> dose. Level  |  |  |  |  |
|  | to be taken one hour after completion of the bolus/infusion.   |  |  |  |  |
|  | If renally impaired, check around the 2 <sup>nd</sup> dose.  |  |  |  |  |
|  | Label your sample tubes and request form clearly with pre and post   |  |  |  |  |
|  | dose level as appropriate.   |  |  |  |  |
| Target assay levels  | Pre-dose (trough) level -less than 1mg/L for endocarditis  |  |  |  |  |
|  | One hour post dose (peak) level: 3-5mg/L for streptococcal or  |  |  |  |  |
|  | enterococcal infections e.g. endocarditis  |  |  |  |  |
| Recommendations  | Pre-dose levels:   |  |  |  |  |
| for dose   | Normal pre-dose (<1mg/L)   |  |  |  |  |
| adjustment based   | - Regimen can be continued   |  |  |  |  |
| on levels being  | - Further pre-dose levels MUST be monitored twice weekly so long as renal  |  |  |  |  |
| taken at correct   | function is stable   |  |  |  |  |
| time   | Pre-dose level is between 1-3mg/L (and renal function unchanged)   |  |  |  |  |
| Diagram  | - Increase the dosing interval e.g. from 12-hourly to 24-hourly  |  |  |  |  |
| Please contact   | Pre-dose greater than 3mg/L  |  |  |  |  |
| your ward Pharmacist or  | - Further gentamicin doses MUST be withheld  |  |  |  |  |
| Consultant   | - Discuss with microbiology before recommencing therapy  |  |  |  |  |
| Microbiologist for   | One-hour post-dose levels:   |  |  |  |  |
| advice on changes   Post-dose level is below the target range (<3mg/L) |  |  |  |  |  |
| to the dose and/or   | - Gentamicin is sub-therapeutic  |  |  |  |  |
| dosing interval.   | - The dose should be increased   |  |  |  |  |
| 3 11 1 2   | Post-dose level is above the target range (>5mg/L); pre-dose level is  |  |  |  |  |
|  | normal (<1mg/L)  |  |  |  |  |
|  | - Reduce the dose  |  |  |  |  |
|  | Both the post-dose (>5mg/L) and pre-dose (>1mg/L) levels are above   |  |  |  |  |
|  | the target range   |  |  |  |  |
|  | - The next dose(s) MUST be omitted   |  |  |  |  |
|  | - Discuss with Microbiology before recommencing therapy  |  |  |  |  |

| Blackpool Teaching Hospitals NHS Foundation Trust |  | ID No. CORP/GUID/313                     |  |  |
|---|--|--|--|--|
| Revision No: 5 Next Review Date: 18/02/2023       |  | Title: Gentamicin Adult Dosing Treatment |  |  |
| UNCONTROLLED COPY WHEN PRINTED                    |  |  |  |  |
| Current Version held on the Intranet              |  |  |  |  |

### Appendix 4: Maximum Body Weight/ Ideal Body Weight Table

This table helps to determine whether patients are obese (i.e. actual body weight 20% over ideal body weight). If patient's actual weight is above the maximum body weight below - the adjusted body weight should be used to calculate gentamicin dose (see formula below). Otherwise, use actual body weight to calculate gentamicin dose.

| Maximum body weight (MBW) table |         |        |          |          |
|---------------------------------|---------|--------|----------|----------|
| Height                          |         | Height | MBW (kg) | MBW (kg) |
| (ft                             | inches) | (cm)   | (male)   | (female) |
| 5'                              | 0"      | 152    | 60       | 55       |
| 5'                              | 1"      | 155    | 62       | 58       |
| 5'                              | 2"      | 158    | 66       | 60       |
| 5'                              | 3"      | 160    | 68       | 62       |
| 5'                              | 4"      | 163    | 71       | 66       |
| 5'                              | 5"      | 165    | 74       | 68       |
| 5'                              | 6"      | 168    | 77       | 71       |
| 5'                              | 7"      | 170    | 79       | 74       |
| 5'                              | 8"      | 173    | 82       | 77       |
| 5'                              | 9"      | 175    | 85       | 79       |
| 5'                              | 10"     | 178    | 88       | 82       |
| 5'                              | 11"     | 180    | 90       | 85       |
| 6'                              | 0"      | 183    | 94       | 88       |
| 6'                              | 1"      | 185    | 96       | 90       |
| 6'                              | 2"      | 188    | 98       | 94       |
| 6'                              | 3"      | 191    | 101      | 97       |
| 6'                              | 4"      | 193    | 104      | 99       |
| 6'                              | 5"      | 195    | 107      | 101      |
| 6'                              | 6"      | 198    | 109      | 105      |
| 6'                              | 7"      | 201    | 113      | 108      |
| 6'                              | 8"      | 203    | 115      | 110      |

Adjusted body weight calculation

Adjusted body weight = ideal body weight + 0.4 (actual body weight - ideal body weight)

| Revision No: 5   | Hospitals NHS Foundation Trust  Next Review Date: 18/02/2023 | Title: Gentamicin Adult Dosing Treatment |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|
| UNCONTROLLED COPY WHEN PRINTED  Current Version held on the Intranet |  |  |  |  |  |  |  |  |

### Appendix 4: Maximum Body Weight/ Ideal Body Weight Table

Ideal Body Weight Tables (based on Devine Formula)

women: Ideal Body Weight (in kg) = 45.5 + 2.3 kg per inch over 5 feet men: Ideal Body Weight (in kg) = 50 + 2.3 kg per inch over 5 feet

|                  | Female |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |       |
|------------------|--------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-------|
| Height<br>Feet   | 5'     | 5'1" | 5'2" | 5'3" | 5'4" | 5'5" | 5'6" | 5'7" | 5'8" | 5'9" | 5'10 | 5'11 | 6'   | 6'1" | 6'2" | 6'3" | 6'4'' |
| Height<br>Inches | 60     | 61   | 62   | 63   | 64   | 65   | 66   | 67   | 68   | 69   | 70   | 71   | 72   | 73   | 74   | 75   | 76    |
| Height<br>cm     | 152    | 155  | 157  | 160  | 163  | 165  | 168  | 170  | 173  | 175  | 178  | 180  | 183  | 185  | 188  | 190  | 193   |
| IBW<br>kg        | 45.5   | 47.8 | 50.1 | 52.4 | 54.7 | 57   | 59.3 | 61.6 | 63.9 | 66.2 | 68.5 | 70.8 | 73.1 | 75.4 | 77.7 | 80   | 82.3  |
|                  | Male   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |       |
| Height<br>Feet   | 5'     | 5'1" | 5'2" | 5'3" | 5'4" | 5'5" | 5'6" | 5'7" | 5'8" | 5'9" | 5'10 | 5'11 | 6'   | 6'1" | 6'2" | 6'3" | 6'4"  |
| Height<br>Inches | 60     | 61   | 62   | 63   | 64   | 65   | 66   | 67   | 68   | 69   | 70   | 71   | 72   | 73   | 74   | 75   | 76    |
| Height<br>Cm     | 152    | 155  | 157  | 160  | 163  | 165  | 168  | 170  | 173  | 175  | 178  | 180  | 183  | 185  | 188  | 190  | 193   |
| IBW<br>kg        | 50     | 52.3 | 54.6 | 56.9 | 59.2 | 61.5 | 63.8 | 66.1 | 68.4 | 70.7 | 73   | 75.3 | 77.6 | 79.9 | 82.2 | 84.5 | 86.8  |

Adapted from Scottish Medicines Consortium NHS Scotland Jan 2013 Resources

| Revision No: 5     | Next Review Date: 18/02/2023  UNCONTROLLED COP | Title: Gentamicin Adult Dosing Treatment |  |  |  |  |
|--------------------|--|--|--|--|--|--|
| Blackpool Teaching | Hospitals NHS Foundation Trust                 | ID No. CORP/GUID/313                     |  |  |  |  |

#### Appendix 5: Gentamicin Flow Chart Do NOT use extended interval dosing for the following groups of patients: (without discussion with pharmacist or microbiologist) **Bronchiectasis** Burns (>20% body surface area) Cystic fibrosis Infective endocarditis – use traditional multiple dosing Renal impairment - unstable or deteriorating renal function - use with care Renal dialysis Age 70 or above Yes No Creatinine Creatinine Clearance less Clearance less than 10mL/min or than 10mL/min or patient anuric patient anuric Yes No No Yes Use 3mg/kg\* od Creatinine Do not use. Do not use. (max 300mg) Clearance equal to Speak to Speak to Round to or greater Microbiology Microbiology nearest 20mg 30mL/min No Yes Use 3mg/kg\* od Use 5mg/kg\* od (max 300mg) (max 500mg) Round to Round to nearest 20mg nearest 20mg \*Use adjusted body weight if obese (i.e. if 20% over ideal body weight) Review need daily and monitor for renal/ototoxicity

| Blackpool Teaching Hos               | spitals NHS Foundation Trust | ID No. CORP/GUID/313                     |  |  |  |  |  |  |
|--------------------------------------|------------------------------|--|--|--|--|--|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023 | Title: Gentamicin Adult Dosing Treatment |  |  |  |  |  |  |
| UNCONTROLLED COPY WHEN PRINTED       |                              |  |  |  |  |  |  |  |
| Current Version held on the Intranet |                              |  |  |  |  |  |  |  |

### **Appendix 6: Equality Impact Assessment Form**

 Department
 Organisation wide
 Service or Policy
 Guideline
 Date Completed:
 September 2012

#### **GROUPS TO BE CONSIDERED**

Deprived communities, homeless, substance misusers, people who have a disability, learning disability, older people, children and families, young people, Lesbian Gay Bi-sexual or Transgender, minority ethnic communities, Gypsy/Roma/Travellers, women/men, parents, carers, staff, wider community, offenders.

#### EQUALITY PROTECTED CHARACTERISTICS TO BE CONSIDERED

Age, gender, disability, race, sexual orientation, gender identity (or reassignment), religion and belief, carers, Human Rights and social economic / deprivation.

| question.  | RESPONS   | IMPACT   |                                     |          |  |
|--|---|--|-------------------------------------|----------|--|
| 40-2000  | Issue   | Action   | Positive                            | Negative |  |
| What is the service, leaflet or policy development? What are its aims, who are the target audience?  | The Procedural Document is to ensure that all members of staff have clear guidance on processes to be followed. The target audience is all staff across the Organisation who undertakes this process. | Raise awareness of the Organisations format and processes involved in relation to the procedural document. | Yes – Clear<br>processes identified |          |  |
| Does the service, leaflet or policy/ development impact on community safety  Crime Community cohesion  | Not applicable to community safety or crime   | N/A  | N/A                                 |          |  |
| Is there any evidence that groups who should benefit do not? i.e. equal opportunity monitoring of service users and/or staff. If none/insufficient local or national data available consider what information you need.  | No  | N/A  | N/A                                 |          |  |
| Does the service, leaflet or development/<br>policy have a negative impact on any<br>geographical or sub group of the<br>population?   | No  | N/A  | N/A                                 |          |  |
| How does the service, leaflet or policy/<br>development promote equality and<br>diversity?   | Ensures a cohesive approach across the<br>Organisation in relation to the procedural<br>document.   | All policies and procedural documents include an EA to identify any positive or negative impacts.          |                                     |          |  |
| Does the service, leaflet or policy/<br>development explicitly include a<br>commitment to equality and diversity and<br>meeting needs? How does it demonstrate<br>its impact?  | The Procedure includes a completed EA which provides the opportunity to highlight any potential for a negative / adverse impact.  |  |                                     |          |  |
| Does the Organisation or service<br>workforce reflect the local population? Do<br>we employ people from disadvantaged<br>groups  | Our workforce is reflective of the local population.  |  |                                     |          |  |
| Will the service, leaflet or policy/ development i. Improve economic social conditions in deprived areas ii. Use brown field sites iii. Improve public spaces including creation of green spaces?                        | NA  |  |                                     |          |  |
| Does the service, leaflet or policy/<br>development promote equity of lifelong<br>learning?  | NA  |  |                                     |          |  |
| Does the service, leaflet or policy/<br>development encourage healthy lifestyles<br>and reduce risks to health?  | NA  |  |                                     |          |  |
| Does the service, leaflet or policy/<br>development impact on transport?<br>What are the implications of this?   | NA  |  |                                     |          |  |
| Does the service, leaflet or policy/development impact on housing, housing needs, homelessness, or a person's ability to remain at home?   | NA  |  |                                     |          |  |
| Are there any groups for whom this policy/ service/leaflet would have an impact? Is it an adverse/negative impact? Does it or could it (or is the perception that it could exclude disadvantaged or marginalised groups? | None identied   |  |                                     |          |  |

| Blackpool Teaching                   | Hospitals NHS Foundation Trust | ID No. CORP/GUID/313 Title: Gentamicin Adult Dosing Treatment |  |  |  |  |  |  |
|--------------------------------------|--------------------------------|---|--|--|--|--|--|--|
| Revision No: 5                       | Next Review Date: 18/02/2023   |   |  |  |  |  |  |  |
| UNCONTROLLED COPY WHEN PRINTED       |                                |   |  |  |  |  |  |  |
| Current Version held on the Intranet |                                |   |  |  |  |  |  |  |

| Appendix 6: Equality Impact Assessment Form  |               |              |              |          |          |  |  |  |
|--|---------------|--------------|--------------|----------|----------|--|--|--|
| Does the policy/development promote access to services and facilities for any                        | No            |              |              |          |          |  |  |  |
| group in particular?   |               |              |              |          |          |  |  |  |
| Does the service, leaflet or   | No            |              |              |          |          |  |  |  |
| policy/development impact on the   | NO            |              |              |          |          |  |  |  |
| environment  |               |              |              |          |          |  |  |  |
|  |               |              |              |          |          |  |  |  |
| During development   |               |              |              |          |          |  |  |  |
| At implementation?   |               |              |              |          |          |  |  |  |
| ACTION:  |               |              |              |          |          |  |  |  |
| Please identify if you are now required to carry out a Full Equality  Yes  No  (Please de appropriat |               |              |              |          |          |  |  |  |
| Name of Author:  | Michelle Wong | Date Signed: |              | Feb 2021 |          |  |  |  |
| Signature of Author:   |               |              |              |          |          |  |  |  |
|  |               |              |              |          |          |  |  |  |
| Name of Lead Person:   |               |              | Date Sig     | ned:     |          |  |  |  |
| Signature of Lead Person:  |               |              |              |          |          |  |  |  |
|  |               |              |              |          |          |  |  |  |
| Name of Manager:   | Rebecca Bond  |              | Date Signed: |          | Feb 2021 |  |  |  |
| Signature of Manager   |               |              |              |          |          |  |  |  |
|  |               |              |              |          |          |  |  |  |